Verbaan 2012.

Trial name or title	Ultra‐early tranexamic acid after subarachnoid haemorrhage. A prospective, randomised, multicenter study
Methods	Multicentre study Random allocation Open treatment with blind endpoint assessment Intention‐to‐treat
Participants	Clinical diagnosis of aneurysmal SAH verified on CT with inclusion within 24 hours of start of symptoms Excluded: no loss of consciousness after the haemorrhage with WFNS grade 1 or 2 on admission in combination with a perimesencephalic haemorrhage; bleeding pattern on CT compatible with a traumatic SAH; treatment for deep vein thrombosis; history of blood coagulation disorder; pregnancy or breastfeeding; severe renal (serum creatinine > 150 mmol/L) or liver failure (AST > 150 U/l or ALT > 150 U/l or AF > 150 U/l or gamma‐GT > 150 U/l); imminent death within 24 hours
Interventions	Standard treatment with additional administration of 1 g tranexamic acid intravenously in 10 minutes, immediately after the diagnosis SAH, succeeded by continuous infusion of 1 g per 8 hours until a maximum of 24 hours
Outcomes	Primary outcome: Modified Rankin Scale score dichotomised as a favourable (0 to 3) or unfavourable (4 to 6) outcome at 6 months after SAH Secondary: case fatality, cause of poor outcome, rebleeding rate, thromboembolic complications, delayed cerebral ischaemia, other complications (hydrocephalus, thromboembolic events, extracranial thrombosis or haemorrhagic complications), care cost
Starting date	January 2013
Contact information	d.verbaan@amc.uva.nl
Notes

CT: computed tomography
 SAH: subarachnoid haemorrhage
 WFNS: World Federation of Neurological Societies